Skip Navigation LinksHome > May 2013 - Volume 257 - Issue 5 > Liver Transplantation for Nonresectable Liver Metastases Fro...
Annals of Surgery:
doi: 10.1097/SLA.0b013e3182823957
Features

Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer

Hagness, Morten MD*,†; Foss, Aksel MD, PhD*,†; Line, Pål-Dag MD, PhD*; Scholz, Tim MD, PhD*; Jørgensen, Pål Foyn MD, PhD*; Fosby, Bjarte MD*,†; Boberg, Kirsten Muri MD, PhD; Mathisen, Øystein MD, PhD§; Gladhaug, Ivar P. MD, PhD†,§; Egge, Tor Skatvedt MD; Solberg, Steinar MD, PhD; Hausken, John MD**; Dueland, Svein MD, PhD††

Collapse Box

Abstract

Objective: The objective of this pilot study was to investigate the potential for long-term overall survival (OS) after liver transplantation for colorectal liver metastases (CLMs).

Background: Patients with nonresectable CLMs have poor prognosis, and few survive beyond 5 years. CLMs are currently considered an absolute contraindication for liver transplantation, although liver transplantation for primary and some secondary liver malignancies shows excellent outcome in selected patients. Before 1995, several liver transplantations for CLMs were performed, but outcome was poor (5-year survival rate: 18%) and liver transplantation for CLMs was abandoned. Since then, the survival rate after liver transplantation in general has improved by almost 30%. On the basis of this, a 5-year survival rate of about 50% after liver transplantation for CLMs could be anticipated.

Methods: In a prospective pilot study, liver transplantation for nonresectable CLMs was performed (n = 21). Main inclusion criteria were liver-only CLMs, excised primary tumors, and at least 6 weeks of chemotherapy.

Results: Kaplan-Meier estimates of the OS rate at 1, 3, and 5 years were 95%, 68%, and 60%, respectively. Metastatic recurrence of disease was common (mainly pulmonary). However, a significant proportion of the recurrences were accessible for surgery, and at follow-up (after median of 27 months; range, 8–60), 33% had no evidence of disease. Hepatic tumor load before liver transplantation, time from primary surgery to liver transplantation, and progressive disease on chemotherapy were identified as significant prognostic factors.

Conclusions: OS exceeds by far reported outcome for chemotherapy, which is the only treatment option available for this patient group. Furthermore, OS is comparable with liver resection for resectable CLMs and survival after repeat liver transplantation for nonmalignant diseases. Selection strategies based on prognostic factors may further improve the outcome (ClinicalTrials.gov: NCT01311453).

© 2013 by Lippincott Williams & Wilkins.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.